Anisa Valina, DO
Critical Care Medicine · Las Vegas, NVNPI 1659719854
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $268 of the $308 with a category attached, or 87.0%. 7 manufacturers reported payments, led by Veran Medical Technologies, Inc. at 34.9% of the total. That places this record below the midpoint for critical care medicine clinicians in NV, where the typical reported total is $382.
Across 7 payments — averaging $44.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Veran Medical Technologies, Inc.$108
- Abiomed$103
- Astellas Pharma US Inc$40
- Sanofi$18
- Actelion Pharmaceuticals US, Inc.$15
- Boston Scientific$12
- plus $12 from 1 others
What the payments were for
- Food & beverage$26887%
- Education$4013%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Veran Medical Technologies, Inc. | 1 | $108 |
| Abiomed | 1 | $103 |
| Astellas Pharma US Inc | 1 | $40 |
| Sanofi | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $15 |
| Boston Scientific | 1 | $12 |
| Boehringer Ingelheim | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$308 in reported general payments places this provider in the 45th percentile of 68 critical care medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 13 | $7,615 |
| XareltoRivaroxaban | 11 | $6,653 |
| Atorvastatin Calcium | 16 | $311 |
Paid to pharmacies, not to this prescriber.
Other critical care medicine in Las Vegas
- Karan GuptaLas Vegas$29K
- Joaquim TavaresLas Vegas$21K
- Ghulam AftabLas Vegas$7K
- Hany GhaliLas Vegas$4K
- Spandan PatelLas Vegas$2K
- Zoltan HorvathLas Vegas$2K
- Michael GaleLas Vegas$2K
- Prashant GundreLas Vegas$1K
- John KotLas Vegas$1K
- Mohamed AlibakhietLas Vegas$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.